Comparison of Markov Model and Dynamic Model in Economic Evaluations for Infectious Diseases: A case of Bictegravir/emtricitabine/tenofovir Treatment-native adults of HIV-1 in China

Author:

wang wenjuan1,Zhou Dachuang1,Zhou Kejia1,Zhang Di1,Li Hao1,Zhang Hongliu1,Jiang Xin1,Wang Ruihua1,Wang Xi2,Tang Wenxi1

Affiliation:

1. China Pharmaceutical University

2. Capital Medical University

Abstract

Abstract

Background: This study aimed to compare the performances between Markov model and dynamic model in economic evaluations for antiretroviral therapy (ART) of HIV, using a case of bictegravir/emtricitabine/tenofovir (B/F/TAF) for treatment-native adults of HIV-1 infection in China. Methods: A Markov model was used to simulate in detail the lifetime treatment of HIV among adult patients with ART with a cycle of one month. A dynamic model was used to consider the effects of ART on preventing transmission among all Chinese adults, with a time frame of 30 years and a cycleof one year. The primary outcomes were total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Sensitivity analyses were conducted for result validation, and the model precision was tested using relative standard deviation (RSD). Results: In Markov model and dynamic model, compared with dolutegravir/lamivudine (DTG/3TC), B/F/TAF incurred higher per-person expenses ($44,381.33 and $30.94 versus $42,160.13 and $29.28) but yielded superior QALYs (12.7788 and 17.9423 vs 12.6310 and 17.9420), resulting in higher ICER for Markov model compared to dynamic model (14,081.23 vs 6,524.03 USD/QALY). The robustness of the results was confirmed in uncertainty analyses, and Markov model exhibited a lower RSD. Conclusion: B/F/TAF is deemed cost-effective in China according to both models, presenting a valuable treatment option despite its higher price in the era of optimized HIV care. The choice of the economic evaluation model influences the ICERs of ART, with dynamic model advantageous for incorporating externality and Markov model noted for its precision.

Publisher

Springer Science and Business Media LLC

Reference68 articles.

1. New progress in HIV/AIDS epidemiology in China;HE N;Chin J Disease Control Prev,2021

2. Progress and achievements of free HIV antiviral treatment in China;Zhang F;Chin J AIDS STD,2022

3. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia. PharmacoEconomics - open. 2021 2021/12/1;5;Belay YB

4. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States;Butler K;J Managed Care Specialty Pharm,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3